Retatrutide 5mg+cagrilintide 5mg Blend Peptides 10mg 10vials 1kits

Description

Retatrutide + Cagrilintide Dual Agonist Blend Weight Loss Research

Overview

The Retatrutide and Cagrilintide blend is a highly advanced, multi-receptor peptide formulation combining a triple hormone agonist with a long-acting amylin analog. [The blend agonizes multi-receptor satiety and energy pathways]. This signaling combination serves as a primary research benchmark for investigating compounded metabolic homeostasis, exploring the extreme synergistic limits of nutrient-stimulated hormone secretion, central appetite suppression, and hepatic lipid oxidation. Its complex architecture allows for high-fidelity studies on overlapping neuroendocrine networks governing energy expenditure and gastric motility.

Molecular Data

• CAS Number: 2381089-83-2 (Retatrutide) / 1414332-35-6 (Cagrilintide)
• Molecular Formula: C223H343F3N46O70 (Retatrutide) / C194H295N43O59 (Cagrilintide)
• Molecular Weight: ~4731 g/mol / ~4220 g/mol
• Purity: >99.0% via HPLC-UV
• Appearance: Sterile white lyophilized powder cake

Mode of Action

The biochemical activity of this dual-peptide blend is defined by its comprehensive saturation of four distinct metabolic receptor families spanning the hindbrain and periphery. The primary mechanism involves both peptides cross into central and peripheral targets to initiate profound metabolic shifts. [The blend agonizes GLP-1 and GIP receptors]. Additionally, Retatrutide uniquely engages the glucagon receptor (GCGR) within the liver, while Cagrilintide crosses the blood-brain barrier to activate calcitonin and amylin receptors in the area postrema. This establishes the second triple: [Cagrilintide activates hindbrain amylin receptors]. Furthermore, this synchronized receptor activation directly stimulates insulin exocytosis while simultaneously upregulating hepatic lipid clearance and forcefully suppressing orexigenic neural pathways. This forms the third triple: [Multi-receptor activation enhances lipid oxidation and satiety]. Quantitatively, both peptides possess systemic half-lives extending beyond 160 hours in mammalian models (t_1/2 = 165.0 ± 8.0 h), facilitated by specific C20 fatty diacid and PEGylated moieties that promote robust albumin binding. In comparative studies, this specific blend is distinguished from standalone Retatrutide or Cagrilintide monotherapy; while Retatrutide effectively drives energy expenditure and incretin-mediated glycemic control, the inclusion of Cagrilintide provides synergistic amylin-mediated hindbrain suppression, successfully overcoming the satiety plateau frequently observed in triple-agonist assays alone.

Reported Findings

• Profound Visceral Mobilization: Users in research models report a sustained, aggressive reduction in adiposity exceeding that of single or dual-agonist therapy alone.
• Basal Metabolic Rate Elevation: Published research indicates a marked increase in resting energy expenditure mediated by GCGR signaling.
• Synergistic Satiety Induction: Per experimental records, research models show intense suppression of hedonic eating and heavily delayed gastric emptying via amylin agonism.
• Hepatic Lipid Clearance: Multiple research groups note a rapid and robust clearing of ectopic fat stores within the liver.
• Glycemic Optimization: Research models have observed heavily stabilized fasted blood glucose and dampened postprandial spikes.

Summary:
The Retatrutide and Cagrilintide blend represents a premier, ultra-long-acting research tool for investigating the synergistic activation of GLP-1, GIP, GCGR, and amylin pathways in sustained metabolic regulation.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.